ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 8, 2021

8:30AM-10:30AM: Abstract Number: 1263

Treatment of Pediatric Lupus Is Associated with Significant Re-Organization of B Cell Chromatin

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Abstract Number: 1339

Treatment Persistence Was Similar at 3 Years in Patients with Psoriatic Arthritis Treated with Ustekinumab (STELARA®) or a Tumor Necrosis Factor Inhibitor in a Prospective Real-World Study

Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)

8:30AM-10:30AM: Abstract Number: 1286

Twenty-Year Trends in Systemic Lupus Erythematosus All–Cause Mortality in Mexico: A Nationwide Health Registry

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Abstract Number: 1198

Ultrasonography of the Median Nerve in Patients with Rheumatoid Arthritis Under Suspicion of Carpal Tunnel Syndrome

RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)

8:30AM-10:30AM: Abstract Number: 1360

Ultrasound Demonstrates Continued Improvement in Psoriatic Arthritis Synovitis and Enthesitis with Secukinumab: 52-week Results from a Phase III Study

Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)

8:30AM-10:30AM: Abstract Number: 1199

Ultrasound in Clinically Suspect Arthralgia: The Role of Power Doppler to Predict Rheumatoid Arthritis Development

RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)

8:30AM-10:30AM: Abstract Number: 1189

Ultrasound Online: A Novel Approach to Teaching Rheumatology Focused Musculoskeletal Ultrasonography to Resident Physicians in Training

Professional Education Poster (1170–1195)

8:30AM-10:30AM: Abstract Number: 1144

Underestimation of the Fracture Risk by the FRAX Formula in Chronic Glucocorticoid Users: A 10-year Longitudinal Validation Study

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster (1135–1149)

8:30AM-10:30AM: Abstract Number: 1305

Undiagnosed Depression in Axial Spondyloarthropathy and the Negative Impact on Patient Outcomes: Results of a Screening Study

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)

8:30AM-10:30AM: Abstract Number: 1218

Unsupervised Clustering Identifies Unique Subsets of Patients in a Racially and Ethnically Diverse Rheumatoid Arthritis Cohort

RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)

8:30AM-10:30AM: Abstract Number: 1340

Upadacitinib Effects on Entheseal Domain in Psoriatic Arthritis Patients – a Pooled “post-hoc” Analysis from Two Phase III Studies (Select PsA 1 and 2)

Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)

8:30AM-10:30AM: Abstract Number: 1150

Use of Energy Conversation Strategies as a Result of the Fatigue Management Education for Individuals with Systemic Sclerosis (FAME-iSS)

Patient Education/Community Programs Poster (1150–1152)

8:30AM-10:30AM: Abstract Number: 1063

Use of Telemedicine for Rheumatology Practice in Queensland, Australia: Experiences Before and During the COVID-19 Pandemic

Health Services Research Poster II: Care Models and Innovation (1061–1082)

8:30AM-10:30AM: Abstract Number: 1395

Utility and Validity of the Southend Pretest Probability Score (SPTPS) in a Giant Cell Arteritis Fast Track Clinic: Analysis in a Spanish Cohort of 297 Patients

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)

8:30AM-10:30AM: Abstract Number: 1401

Utility of CRP and ESR in the Assessment of Giant Cell Arteritis Relapse in a Phase 2 Trial of Mavrilimumab

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].